Presentations

      Post-market evidence on alternative nicotine-containing products

      Roulet, S.

      Conference date
      Jun 25, 2021
      Conference name
      Bulgarian Pharmaceutical Days 2021
      Topic
      Summary

      Below is transcript of the video introduction:

      Good morning, good afternoon to everyone listening to this recorded session. I'm very pleased to be a speaker for the Bulgarian Pharmaceutical Days. I am Steve Roulet, and I'm the Global Head of Behavioral Research Insights at Philip Morris. Today, I'm going to talk about post-market evidence related to alternative nicotine-containing products. I have been working with Philip Morris for about 20 years, and I've been involved in all pre- and post-marketing studies with the aim to assess the perception and the behavior of adult tobacco and nicotine-containing product user and adult non-tobacco and nicotine-containing product user, related to IQOS, which is Philip Morris's heated tobacco product.

      During today's presentation, I will cover quite a lot of ground, starting with the overall harm reduction concept. Then I will move to Philip Morris’ overall scientific assessment program for Philip Morris’ smoke-free products with a particular focus on post-market studies that we have implemented in Japan, Italy, and Germany, but also showing you results form a recent study conducted in the beginning of last year in Bulgaria. Before closing my presentation, I will present you key results from independent studies showing that the prevalence of use of heated tobacco products among former and never tobacco and nicotine-containing product user, including youth, is low in countries where IQOS has been already commercialized.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.